Corpus Intelligence IC Memo — RANKEN JORDAN 2026-04-26 10:37 UTC
IC Memo — RANKEN JORDAN
Investment Committee Memorandum | MO | 60 beds | Grade C | EBITDA uplift $5.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

RANKEN JORDAN

CCN 263303 | ST. LOUIS, MO | 60 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

RANKEN JORDAN is a 60-bed safety-net/medicaid heavy in ST. LOUIS, MO with $67.3M in net patient revenue and a 22.2% operating margin. The hospital serves a payer mix of 0.2% Medicare, 26.6% Medicaid, and 73.3% commercial.

Thesis: Turnaround. Our ML models identify $5.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 22.2% to 29.6% (+736bps).

Net Revenue HCRIS$67.3M
Current EBITDA COMPUTED$15.0M
Operating Margin COMPUTED22.2%
Occupancy HCRIS79.9%
Revenue / Bed COMPUTED$1.1M
Net-to-Gross HCRIS82.7%
Distress Probability ML51.5%

2. Market Context & Competitive Position

138
MO Hospitals
-6.2%
State Median Margin
50
Comparable Hospitals

MO has 138 Medicare-certified hospitals with a median operating margin of -6.2%. The target's margin of 22.2% places it above the state median. Among 50 size-comparable peers (30-120 beds), the median margin is -7.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (30-120), prioritizing same-state peers. 50 hospitals in the comp set.

HospitalStateBedsRevenueMargin
RANKEN JORDAN (Target)MO60$67.3M22.2%
LAKE REGIONAL HEALTH SYSTEMMO105$226.8M-2.7%
HANNIBAL REGIONAL HOSPITALMO86$226.2M-6.8%
CAPITAL REGION MEDICAL CENTERMO100$224.0M-17.7%
BARNES JEWISH WEST COUNTY HOSPMO68$221.1M4.9%
SAINT LUKES NORTH HOSPITALMO108$183.6M-6.4%
CITIZENS MEMORIAL HOSPITAL DISMO52$178.3M-19.3%
BARNES JEWISH ST. PETERS HOSPIMO110$177.0M2.7%
UNIVERSITY HEALTH LAKEWOOD MEDMO117$158.8M-34.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.4M+210bp18mo
Cost to Collect4.5%2.5%$1.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$819K+122bp9mo
Clean Claim Rate88.0%96.0%$43K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.4M
Cost to Collect
$1.3M
Denial Rate Reduction
$1.3M
A/R Days Reduction
$819K
Clean Claim Rate
$43K
Total EBITDA Uplift$5.0M
Current EBITDA$15.0M
+ RCM Uplift+$5.0M
Pro Forma EBITDA$19.9M
Current Margin22.2%
Pro Forma Margin29.6%
WC Released (1x)$2.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$23.0M$148.2M6.44x45.1%
Base (11x exit)10.0x11.0x$23.0M$170.5M7.41x49.3%
Bull Case9.0x11.0x$20.7M$194.4M9.38x56.5%
Bull (12x exit)9.0x12.0x$20.7M$218.1M10.53x60.1%
Bear Case11.0x10.0x$25.3M$116.0M4.58x35.6%
Bear (11x exit)11.0x11.0x$25.3M$135.8M5.36x39.9%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (26.6%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 51.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 50 hospitals with 30-120 beds
  • Same-state prioritization (n=51)
  • Comp margins: P25=-16.3% / P50=-7.6% / P75=7.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.